Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in pa...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
פורמט: Article
שפה:English
יצא לאור: Wiley 2023-08-01
סדרה:Cancer Medicine
נושאים:
ipilimumab
lymph node metastasis
neoplasm metastasis
nivolumab
renal cell carcinoma
survival rate
גישה מקוונת:https://doi.org/10.1002/cam4.6306

אינטרנט

https://doi.org/10.1002/cam4.6306

פריטים דומים